结合Obinutuzumab与放射治疗耐火DLBCL:回顾性安全性和有效性分析
Brett A Morris1, Emily C Merfeld1, Adam R Burr1
1Department of Human Oncology, Department of Internal Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.
Advances in radiation oncology
|May 27, 2024
概括
将奥比努图祖马布与放射治疗结合使用,可为复发性扩散型大B细胞淋巴瘤 (DLBCL) 提供安全有效的治疗方法. 这种方法证明了耐久的疾病控制和耐药DLBCL患者的长期存活.
科学领域:
- 血液学 血液学 血液学
- 在瘤学瘤学.
- 辐射瘤学 辐射瘤学
背景情况:
- 大约30%的扩散型大B细胞淋巴瘤 (DLBCL) 患者经历了化学治疗后的复发或耐药性疾病.
- 对于无法接受干细胞移植或CAR T细胞治疗等激进疗法的DLBCL患者,存在有限的治疗选择.
研究的目的:
- 对复发性DLBCL的OBINUTUSUZUMAB与细胞还原辐射联合治疗的安全性和有效性进行调查.
- 评估这种组合在那些已经耗尽其他治疗途径的耐火性疾病患者中.
主要方法:
- 在2016年至2022年期间接受治疗的7名耐火DLBCL患者的回顾性审查.
- 治疗涉及对所有疾病部位的外部光束辐射,同时使用辅助性obinutuzumab.
- 使用常用术语标准对不良事件v5.0评估的安全性;使用卡普兰-梅尔分析通过无进展生存率 (PFS) 和整体生存率 (OS) 评估的疗效.
主要成果:
- 在这7名患者中,没有观察到3级或更高的与治疗相关的毒性.
- 在7名患者中,有4名在最初的辐射后成像中,在辐射部位实现了完全反应.
- 中位数无进展生存期为30个月,中位数整体生存期为30个月.
结论:
- 辐射和奥比努祖马布的组合在治疗不耐药的DLBCL患者中耐受良好.
- 这种组合疗法在一组患者中显示出持久控制疾病和延长生存的潜力.
- 这种方法为耐火DLBCL患者提供了可行的治疗选择,治疗选择有限.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
12.1K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...